Blogs
Healthcare and Medtech Research Reports
Feb 13, 2026
Summary Bardet–Biedl syndrome (BBS) is a rare, genetically heterogeneous disorder that affects more than 5,000 individuals in the United States. A major therapeutic milestone was the approval of IMCIVREE (setmelanotide), the first targeted MC4R agonist therapy addressing BBS-related obesity. Gene th...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper